Linkedin
RLS logo_header
Linkedin

Taiho Pharmaceutical and Guardant Health to Develop Therapies for Early-Stage, Recurrent Cancer Using Real-World Data Including Genomic Profiling of MRD

Takeshi Sagara, Taiho Pharmaceutical’s Executive Director, Clinical Development and Medical Affairs, Discovery & Preclinical Research, said, “We believe that future anticancer drug discovery focusing on research and development not only for advanced cancer but also for early-stage recurrent cancer, with an eye on the patient’s journey, will lead to long-term survival and ultimately the overcoming of cancer. Through our collaboration with Guardant Health, we aim to identify and develop biomarker signatures, that arise in early-stage recurrence and contribute to the creation of next-generation treatment methods.”

Read the full story on "Taiho Pharmaceutical and Guardant Health to Develop Therapies for Early-Stage, Recurrent Cancer Using Real-World Data Including Genomic Profiling of MRD"

Share:

More News

FDA provides Feedback in Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors

“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across

First Patient dosed in Ph 3 RASolve 308 Trial of Zoldonrasib + Pembrolizumab and Chemo in 1L Metastatic RAS G12D Non-Squamous NSCLC

“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed

Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621

“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three

First Patients enrolled in Standard of Care Chemo Combination Cohorts of Global Ph 1/2 ASCEND Trial of CR-001

“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000